Vitamin B12 level in peripheral arterial disease

Katalin S. Zsóri, Zoltán Csiki, E. Katona, Z. Bereczky, Amir Houshang Shemirani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hyperhomocysteinemia is considered a risk factor for atherosclerosis. Methyltetrahydrofolate reductase (MTHFR) gene mutation and low level of plasma vitamin B12 and folate could take part in the etiology of peripheral arterial disease (PAD). We examined whether plasma vitamin B12 and folate levels and MTHFR-C677T polymorphism are associated with the risk of PAD. The study comprised 293 patients (107 females, 186 males, mean age of 66 ± SEM0.7 years) and 293 sex-matched control subjects (mean age of 62 ± SEM0.8 years). We also determined plasma lipid profile, hs-CRP, creatinine, vitamin B12, folate and total homocysteine (tHcy) for all patients and controls. Odds ratios were non-significant for different genotypes of MTHFR-C677T polymorphism. There was a significant lower level of vitamin B12 in PAD patients. 43 and 25 % of patient and control populations were in the lowest quartile of vitamin B12 (12 in the lowest quartile significantly increased tHcy level in PAD patients, and it was independent of plasma folate level. Low level of plasma vitamin B12 was independently associated with hyperhomocysteinemia in PAD patients. The prevalence of the MTHFR-C677T mutation was not significantly different in patients with PAD compared with controls.

Original languageEnglish
Pages (from-to)77-83
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume36
Issue number1
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Peripheral Arterial Disease
Vitamin B 12
Folic Acid
Oxidoreductases
Hyperhomocysteinemia
Homocysteine
Mutation
Creatinine
Atherosclerosis
Odds Ratio
Genotype
Lipids
Population
Genes

Keywords

  • Folate
  • Methyltetrahydrofolate reductase
  • Peripheral arterial disease
  • Vitamin B

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Vitamin B12 level in peripheral arterial disease. / Zsóri, Katalin S.; Csiki, Zoltán; Katona, E.; Bereczky, Z.; Shemirani, Amir Houshang.

In: Journal of Thrombosis and Thrombolysis, Vol. 36, No. 1, 07.2013, p. 77-83.

Research output: Contribution to journalArticle

Zsóri, Katalin S. ; Csiki, Zoltán ; Katona, E. ; Bereczky, Z. ; Shemirani, Amir Houshang. / Vitamin B12 level in peripheral arterial disease. In: Journal of Thrombosis and Thrombolysis. 2013 ; Vol. 36, No. 1. pp. 77-83.
@article{17ad5a36a9a54f9cbb2ff6cd4871edda,
title = "Vitamin B12 level in peripheral arterial disease",
abstract = "Hyperhomocysteinemia is considered a risk factor for atherosclerosis. Methyltetrahydrofolate reductase (MTHFR) gene mutation and low level of plasma vitamin B12 and folate could take part in the etiology of peripheral arterial disease (PAD). We examined whether plasma vitamin B12 and folate levels and MTHFR-C677T polymorphism are associated with the risk of PAD. The study comprised 293 patients (107 females, 186 males, mean age of 66 ± SEM0.7 years) and 293 sex-matched control subjects (mean age of 62 ± SEM0.8 years). We also determined plasma lipid profile, hs-CRP, creatinine, vitamin B12, folate and total homocysteine (tHcy) for all patients and controls. Odds ratios were non-significant for different genotypes of MTHFR-C677T polymorphism. There was a significant lower level of vitamin B12 in PAD patients. 43 and 25 {\%} of patient and control populations were in the lowest quartile of vitamin B12 (12 in the lowest quartile significantly increased tHcy level in PAD patients, and it was independent of plasma folate level. Low level of plasma vitamin B12 was independently associated with hyperhomocysteinemia in PAD patients. The prevalence of the MTHFR-C677T mutation was not significantly different in patients with PAD compared with controls.",
keywords = "Folate, Methyltetrahydrofolate reductase, Peripheral arterial disease, Vitamin B",
author = "Zs{\'o}ri, {Katalin S.} and Zolt{\'a}n Csiki and E. Katona and Z. Bereczky and Shemirani, {Amir Houshang}",
year = "2013",
month = "7",
doi = "10.1007/s11239-012-0807-6",
language = "English",
volume = "36",
pages = "77--83",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Vitamin B12 level in peripheral arterial disease

AU - Zsóri, Katalin S.

AU - Csiki, Zoltán

AU - Katona, E.

AU - Bereczky, Z.

AU - Shemirani, Amir Houshang

PY - 2013/7

Y1 - 2013/7

N2 - Hyperhomocysteinemia is considered a risk factor for atherosclerosis. Methyltetrahydrofolate reductase (MTHFR) gene mutation and low level of plasma vitamin B12 and folate could take part in the etiology of peripheral arterial disease (PAD). We examined whether plasma vitamin B12 and folate levels and MTHFR-C677T polymorphism are associated with the risk of PAD. The study comprised 293 patients (107 females, 186 males, mean age of 66 ± SEM0.7 years) and 293 sex-matched control subjects (mean age of 62 ± SEM0.8 years). We also determined plasma lipid profile, hs-CRP, creatinine, vitamin B12, folate and total homocysteine (tHcy) for all patients and controls. Odds ratios were non-significant for different genotypes of MTHFR-C677T polymorphism. There was a significant lower level of vitamin B12 in PAD patients. 43 and 25 % of patient and control populations were in the lowest quartile of vitamin B12 (12 in the lowest quartile significantly increased tHcy level in PAD patients, and it was independent of plasma folate level. Low level of plasma vitamin B12 was independently associated with hyperhomocysteinemia in PAD patients. The prevalence of the MTHFR-C677T mutation was not significantly different in patients with PAD compared with controls.

AB - Hyperhomocysteinemia is considered a risk factor for atherosclerosis. Methyltetrahydrofolate reductase (MTHFR) gene mutation and low level of plasma vitamin B12 and folate could take part in the etiology of peripheral arterial disease (PAD). We examined whether plasma vitamin B12 and folate levels and MTHFR-C677T polymorphism are associated with the risk of PAD. The study comprised 293 patients (107 females, 186 males, mean age of 66 ± SEM0.7 years) and 293 sex-matched control subjects (mean age of 62 ± SEM0.8 years). We also determined plasma lipid profile, hs-CRP, creatinine, vitamin B12, folate and total homocysteine (tHcy) for all patients and controls. Odds ratios were non-significant for different genotypes of MTHFR-C677T polymorphism. There was a significant lower level of vitamin B12 in PAD patients. 43 and 25 % of patient and control populations were in the lowest quartile of vitamin B12 (12 in the lowest quartile significantly increased tHcy level in PAD patients, and it was independent of plasma folate level. Low level of plasma vitamin B12 was independently associated with hyperhomocysteinemia in PAD patients. The prevalence of the MTHFR-C677T mutation was not significantly different in patients with PAD compared with controls.

KW - Folate

KW - Methyltetrahydrofolate reductase

KW - Peripheral arterial disease

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=84879228480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879228480&partnerID=8YFLogxK

U2 - 10.1007/s11239-012-0807-6

DO - 10.1007/s11239-012-0807-6

M3 - Article

C2 - 22983814

AN - SCOPUS:84879228480

VL - 36

SP - 77

EP - 83

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -